![Travis Whitfill](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 385 $ al 31/05/2026
Travis Whitfill is the founder of Azitra, Inc., founded in 2014, holding the titles of Chief Operating Officer, Secretary & Director.
Dr. Whitfill is currently a Professor at Yale University since 2018.
Former jobs include Director at 410 Medical, Inc. from 2017 to 2019, Director at Immusoft Corp., Director at SIRPant Immunotherapeutics, Inc. from 2021 to 2023, Independent Director at IN8bio, Inc. from 2018 to 2025, Partner at BIOS Equity Partners LP from 2015 to 2023, and Partner at BIOS Capital Management LP from 2015 to 2023.
Education history includes undergraduate studies at Dallas Baptist University, graduate studies at Yale University, and graduate studies at University College London.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
AZITRA INC 0,01 % | 24/04/2026 | 1.676 ( 0,01 % ) | 385 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| AZITRA, INC. | Fundador | 02/01/2014 |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/03/2018 |
| Empresas | Cargo | Fin |
|---|---|---|
| IN8BIO, INC. | Director/Miembro de la Junta | 09/05/2025 |
BIOS Capital Management LP
 BIOS Capital Management LP Investment ManagersFinance BIOS Partners invests in companies located in the United States. The firm targets companies operating in the fields of biotechnology and medical device sectors. It provides financing for early and later stage capital requirements. | Inversor de Capital Privado | 01/06/2023 |
BIOS Equity Partners LP
 BIOS Equity Partners LP Investment ManagersFinance Functions as private equity firm | Corporate Officer/Principal | 01/06/2023 |
SIRPant Immunotherapeutics, Inc.
 SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology Develops adoptive cell therapy | Director/Miembro de la Junta | 01/06/2023 |
410 Medical, Inc.
 410 Medical, Inc. Medical SpecialtiesHealth Technology Develops medical devices | Director/Miembro de la Junta | 01/07/2019 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
Immusoft Corp.
 Immusoft Corp. Medical/Nursing ServicesHealth Services Provides disease curing services through immune cells | Health Services |
410 Medical, Inc.
410 Medical, Inc. Medical SpecialtiesHealth Technology Develops medical devices | Health Technology |
Dallas Baptist University
 Dallas Baptist University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BIOS Capital Management LP
BIOS Capital Management LP Investment ManagersFinance BIOS Partners invests in companies located in the United States. The firm targets companies operating in the fields of biotechnology and medical device sectors. It provides financing for early and later stage capital requirements. | Finance |
Azitra, Inc.
 Azitra, Inc. Pharmaceuticals: MajorHealth Technology Operates as an clinical biopharmaceutical company that develops and commercializes therapies for precision dermatology | Health Technology |
BIOS Equity Partners LP
BIOS Equity Partners LP Investment ManagersFinance Functions as private equity firm | Finance |
IN8bio, Inc.
 IN8bio, Inc. BiotechnologyHealth Technology Operates as a biotechnology company focused on delivering a novel off-the-shelf product for the treatment of cancer | Health Technology |
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology Develops adoptive cell therapy | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
